Growth from birth to adulthood in a patient with the neonatal form of Bartter syndrome

Area of Science:

• Pediatric Endocrinology
• Nephrology
• Genetics

Background:

• Neonatal Bartter syndrome is a rare genetic disorder affecting kidney function.
• Early management focuses on fluid and electrolyte balance.

Observation:

• A patient with neonatal Bartter syndrome experienced suboptimal growth with initial therapies (fluids, potassium, triamterene).
• Spironolactone and potassium supplementation led to catch-up growth.
• Indomethacin initiation at age 9 resulted in accelerated growth and reduced polyuria/hypercalciuria.

Findings:

• Prostaglandin synthetase inhibitors (indomethacin) significantly improved growth velocity in this patient.
• Normal puberty and adult height (162 cm) were achieved.
• Therapy with prostaglandin synthetase inhibitors appears most effective for neonatal Bartter syndrome.

Implications:

• Early and optimized pharmacotherapy is crucial for achieving normal growth outcomes in neonatal Bartter syndrome.
• Prostaglandin synthetase inhibitors represent a key therapeutic strategy for managing growth deficits.
• This case highlights the long-term benefits of targeted treatment for rare genetic kidney diseases.